This is a prospective, single-blinded, randomized study to evaluate the efficacy and safety of CEGP003 in patients with acute peptic ulcers bleeding, compared to endoscopic epinephrine injection therapy.

CEGP003 is wound dressing solution containing Hydroxyethyl-cellulose and EGF. Epidermal growth factor (EGF) stimulates cell growth and differentiation by binding to its receptor, which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a peptic ulcers bleeding.

Inclusion Criteria:

• Peptic ulcer with high-risk stigmata of recent hemorrhage (Forrest class IA, IB, IIA and IIB)

Exclusion Criteria:

• Subjects who have a history of malignant tumor in upper gastro-intestinal site
• Subjects with platelet and coagulation dysfunction (PLT < 50E9/L, INR > 2)
• Subjects that have taken anticoagulant drugs or non-steroidal anti-inflammatory drugs within 72 hours after the treatment
• Subjects with one or more bleeding sources
• Subjects who are pregnant or breast-feeding
• Subject who are allergic or have a hypersensitive reaction to Hydroxyethyl-cellulose or EGF
• Subjects who have undergone endoscopically therapies within the last 7 days
• Subjects who are considered not suitable for the study by significant disease
• Subjects who are not able to comply with the study requirements
• Subjects who are currently enrolled in another clinical study which can impact the study within 30 days of screening
• Subjects who are considered not suitable for the study by the investigator